Highlights Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
26.33 ^USD	+3.25%		+0.30%	-21.96%

Mar. 13	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Mar. 13	Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	CI
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	Feb. 29	MT
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	Feb. 29	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	Feb. 29	MT
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy	Feb. 15	CI
Pacira BioSciences Receives Brand Pharmaceuticals Agreement With Premier, Inc	Feb. 07	CI
Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus	Jan. 04	MT
Pacira BioSciences Says US FDA Approves Exparel Application for Two Additional Nerve Block Indications	Nov. 10	MT
Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications	Nov. 10	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q3 Revenue $163.9M, vs. Street Est of $172.9M	Nov. 02	MT
Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023	Nov. 02	CI
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q2 Revenue $169.5M, vs. Street Est of $175M	23-08-02	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q2 EPS $0.78, vs. Street Est of $0.76	23-08-02	MT
Pacira BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Pacira BioSciences Q1 Adjusted Earnings Fall, Revenue Rises	23-05-03	MT
Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023	23-05-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Highlights

Filters